Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UIO-S24
- Development stage
- Preclinical
- Lead developer
- TransCode Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
UIO-S24 is an investigational RNA-based therapeutic candidate being developed by TransCode Therapeutics for the treatment of muscle-invasive bladder cancer (MIBC). The drug was originally part of the pipeline of Polynoma, which was subsequently acquired by TransCode Therapeutics. UIO-S24 is currently in the preclinical stage of development and is designed to utilize RNA therapy to modulate gene expression associated with bladder cancer progression. While the specific molecular target has not been publicly disclosed, the candidate is part of a broader effort to apply TransCode's RNA delivery platform to solid tumor indications beyond metastatic disease.
Beyond the preview
Go deeper on UIO-S24.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UIO-S24.